Influence of Oral and Percutaneous Estrogen Therapy on the Lipoprotein Particle Profile of Postmenopausal Women

  • J. M. Bard
  • P. Amouyel
  • J. C. Fruchart
Conference paper
Part of the Recent Developments in Lipid and Lipoprotein Research book series (LIPID)


Lipids in women change towards a more atherogenic profile, basically an increase in LDL, at menopause [9]. Estrogen therapy which is used to treat the symptoms of menopause, also leads to changes in the lipid profile, most often a decrease in LDL and an increase in HDL and triglycerides


Cholesterol Efflux Lipoprotein Particle Lipid Research Clinic Percutaneous Therapy Inclusion Time 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Agnani G, Bard JM, Candelier L et al. (1991) Interaction of Lp B, Lp B:E, Lp B: C-III and Lp B:C-III: E lipoproteins with the LDL receptor on HeLa cells. Arteriosclerosis 11: 1021–1029.CrossRefGoogle Scholar
  2. 2.
    Alaupovic P (1982) The role of apoliproteins in lipid transport processes. Ric Clin Lab 12: 3–21.PubMedGoogle Scholar
  3. 3.
    Barbaras R, Puchois P, Fruchart JC et al. (1987) Cholesterol efflux from cultured adipose cells is mediated by Lp AI particles but not by Lp AI:AII particles. Biochem Biophys Res Commun 142: 63–69.PubMedCrossRefGoogle Scholar
  4. 4.
    Bard JM, Parra HJ, Douste-Blazy P, Fruchart JC (1990) Effect of pravastatin, an HMG CoA Reductase inhibitor, and cholestyramine, a bile acid sequestrant, on lipoprotein particles defined by their apolipoprotein composition. Metabolism 39: 269–273.PubMedCrossRefGoogle Scholar
  5. 5.
    Cambien F, Parra HJ, Arveiler D et al. (1990) Lipoprotein particles in patients with myocardial infarction and controls. Arteriosclerosis 82: 111–349 (abstr. 1380).Google Scholar
  6. 6.
    De Lignieres B, Basdevant A, Thomas G et al. (1985) Biological effects of estradiol 17 beta in postmenopausal women: oral versus percutaneous administration. J Clin End Metab 62: 536–541.CrossRefGoogle Scholar
  7. 7.
    Frick MH, Ello O, Haapa K etal. (1987) Helsinki heart study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors and incidence of coronary heart disease. N Engl J Med 317: 1237–245.PubMedCrossRefGoogle Scholar
  8. 8.
    Kandoussi A, Cachera C, Parsy D, Bard JM, Fruchart JC (1991) Quantitative determination of different apolipoprotein B containing lipoproteins by an enzyme linked immunosorbent assay: apo B with apo C-III and apo B with apo E. J Immunoassay 12: 305–323.CrossRefGoogle Scholar
  9. 9.
    Kannel NB, Hjortland MC, McNamara PM, Gordon T (1976) Menopause and risk of cardiovascular disease: the Framingham Study. Ann Intern Med 85: 447–452.PubMedGoogle Scholar
  10. 10.
    Lipid Research Clinics Program (1984) The lipid Research Clinics Coronary Prevention Trial results: II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 251: 365–374.CrossRefGoogle Scholar
  11. 11.
    Parra HJ, Mezdour H, Ghalim N, Bard JM, Fruchart JC (1990) Differential electroimmunoassay on ready to use plates for human Lp Al lipoprotein particles. Clin Chem 8: 1431–1435.Google Scholar
  12. 12.
    Puchois P, Kandoussi A, Fievet P et al. (1987) Apolipoprotein Al containing lipoproteins in coronaary artery disease. Atherosclerosis 68: 35–40.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1993

Authors and Affiliations

  • J. M. Bard
  • P. Amouyel
  • J. C. Fruchart

There are no affiliations available

Personalised recommendations